All In Biotech

Drug Trial Radar · NCT07888075

Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

A Phase 2/3 Randomized, Double-Blind Study of Rilogrotug Versus Placebo in the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 950 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

950

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Mar 2030

Study completion Oct 2031

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm). Adult participants with cachexia who have also been diagnosed with metastatic colorectal or non-small cell lung cancer will be enrolled. The primary hypothesis is that after 12 weeks, rilogrotug will cause an increase from baseline in body weight and appetite (as measured by the Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale \[FAACT-5IASS\] questionnaire) compared to placebo.

Conditions

  • Cachexia; Cancer
  • Cachexia
  • Cachexia-Anorexia Syndrome
  • Metastatic Colorectal Cancer (CRC)
  • Metastatic Non-small Cell Lung Cancer (NSCLC)
  • Weight Loss
  • Anorexia

Interventions

  • RilogrotugBiological

    Rilogrotug (AV-380) is a humanized immunoglobulin G1 kappa monoclonal antibody that binds to growth differentiation factor-15 (GDF-15).

  • PlaceboBiological

    Placebo for this study will be normal saline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
  2. Phase 2 (A): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
  3. Phase 3 (B): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
  4. Phase 3 (B): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
  5. Phase 3 (C): To evaluate the effect of rilogrotug compared to placebo on weight gainTime frame: 12 weeks
  6. Phase 3 (C): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale scoreTime frame: 12 weeks
  7. OLE (D): To evaluate the safety and tolerability of long-term rilogrotug administrationTime frame: 52 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.